QIAGEN Acquisition Extends Diagnostics Range

QIAGEN has acquired the PCR diagnostics company artus, in a move that now allows QIAGEN to offer preanalytical sample preparation and diagnostic assay solutions to its partners in molecular diagnostics. The acquisition further allows QIAGEN to broadening the tests available on current diagnostic platforms fuelling growth in molecular diagnostics. Under the terms of the agreement, QIAGEN will pay approximately $39.2 million in cash in exchange for all of the outstanding capital stock of artus.

()a href="http://www.drugresearcher.com/news/news-ng.asp?n=60345-qiagen-acquisition-extends" target="_blank">DrugResearcher.com